EDUCATION

Undergraduate Degree

  • University of Washington , 1998 , Seattle , WA

Graduate Degree

PhD, Biophysics
  • Harvard University , 2004 , Cambridge , MA

Medical School

  • Harvard Medical School , 2006 , Boston , MA

Internship

  • Boston Children's Hospital , 2009 , Boston , MA

Fellowship

Pediatric Cardiology
  • Boston Children's Hospital , 2011 , Boston , MA

Fellowship

Electrophysiology
  • Boston Children's Hospital , 2013 , Boston , MA

Philosophy of Care

Caring for patients is a humbling and tremendous privilege. Working with patients and their families to understand their cardiac condition and devise a management strategy together is a deeply rewarding experience. Understanding each individual patient's story is critically important to providing the highest quality care. This is especially true with patients that have forms of inherited cardiac conditions. Working in the Inherited Cardiac Arrhythmia Program provides a unique opportunity to combine my knowledge of basic cardiovascular science with the latest clinical research to help treat patients with channelopathies and other forms of genetic heart disease. Caring for patients is also tremendously inspiring and directly influences my work as a research scientist to develop novel therapies for patients with inherited cardiac disease.

PROFESSIONAL HISTORY

I went to the University of Washington in Seattle where I studied physics and biochemistry. I was lucky enough to work on a number of different research projects ranging from high-energy nuclear physics to microgravity. My medical degree and PhD in biophysics are from Harvard Medical and MIT, where I had the opportunity to work with Dr. David Clapham. Following graduation, I did my internship and residency in pediatrics at the Boston Combined Residency Program. It was here, working with patients at Boston Medical Center, that I developed my interest in long-term care of patients and their families.

I completed a fellowship in pediatric cardiology and acquired additional specialized training in electrophysiology and research. I started on staff at Boston Children's Hospital in 2013 as both a clinical electrophysiologist and a basic research scientist in the fields of inherited cardiac disease and arrhythmia. Under the mentorship of Dr. William Pu, I have developed a program to use induced pluripotent stem cells from patients as models of human cardiac disease to improve therapies for patients with inherited arrhythmia disorders.

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Cardiology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Increased ROS-Mediated CaMKII Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome. Circulation. 2021 Apr 01. View abstract
  2. Two sides of the same coin: new insights into mechanisms of ventricular fibrillation. Cardiovasc Res. 2021 Mar 21; 117(4):983-984. View abstract
  3. Risk Factors for Early Recurrence Following Ablation for Accessory Pathways: The Role of Consolidation Lesions. Circ Arrhythm Electrophysiol. 2020 11; 13(11):e008848. View abstract
  4. Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping. Stem Cells Transl Med. 2021 Jan; 10(1):68-82. View abstract
  5. Paediatric/congenital cardiology physician scientists-An endangered species. Eur J Clin Invest. 2020 Oct; 50(10):e13367. View abstract
  6. MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. J Clin Invest. 2020 09 01; 130(9):4663-4678. View abstract
  7. Value of provocative electrophysiology testing in the management of pediatric patients after congenital heart surgery. Pacing Clin Electrophysiol. 2020 09; 43(9):901-907. View abstract
  8. Gene therapy for inherited arrhythmias. Cardiovasc Res. 2020 Jul 15; 116(9):1635-1650. View abstract
  9. CITED4 Protects Against Adverse Remodeling in Response to Physiological and Pathological Stress. Circ Res. 2020 Aug 14; 127(5):631-646. View abstract
  10. Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease. J Am Heart Assoc. 2020 05 18; 9(10):e016322. View abstract
  11. AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. Circ Res. 2020 04 10; 126(8):1024-1039. View abstract
  12. Low mortality in fetal supraventricular tachycardia: Outcomes in a 30-year single-institution experience. J Cardiovasc Electrophysiol. 2020 05; 31(5):1105-1113. View abstract
  13. Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. Heart Rhythm. 2020 06; 17(6):984-990. View abstract
  14. Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. Circulation. 2020 01 28; 141(4):285-300. View abstract
  15. Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. J Am Coll Cardiol. 2019 07 23; 74(3):346-358. View abstract
  16. Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue. Circulation. 2019 07 30; 140(5):390-404. View abstract
  17. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II. Circulation. 2019 07 30; 140(5):405-419. View abstract
  18. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 03 06; 11(482). View abstract
  19. Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. Circ Genom Precis Med. 2019 03; 12(3):e002463. View abstract
  20. Differentiation of fasciculoventricular fibers from anteroseptal accessory pathways using the surface electrocardiogram. Heart Rhythm. 2019 07; 16(7):1072-1079. View abstract
  21. The Real-World Utility of the LINQ Implantable Loop Recorder in Pediatric and Adult Congenital Heart Patients. JACC Clin Electrophysiol. 2019 02; 5(2):245-251. View abstract
  22. Dual-Site Ventricular Pacing in Patients With Fontan Physiology and Heart Block: Does it Mitigate the Detrimental Effects of Single-Site Ventricular Pacing? JACC Clin Electrophysiol. 2018 10; 4(10):1289-1297. View abstract
  23. Channelopathy as a SUDEP Biomarker in Dravet Syndrome Patient-Derived Cardiac Myocytes. Stem Cell Reports. 2018 09 11; 11(3):626-634. View abstract
  24. Utility of incomplete right bundle branch block as an isolated ECG finding in children undergoing initial cardiac evaluation. Congenit Heart Dis. 2018 May; 13(3):419-427. View abstract
  25. Low molecular weight heparin as an anticoagulation strategy for left-sided ablation procedures. Congenit Heart Dis. 2018 Mar; 13(2):222-225. View abstract
  26. Genotype-phenotype-guided medical and surgical intervention in long QT syndrome. HeartRhythm Case Rep. 2018 Jan; 4(1):14-17. View abstract
  27. Mitochondrial Cardiomyopathy Caused by Elevated Reactive Oxygen Species and Impaired Cardiomyocyte Proliferation. Circ Res. 2018 01 05; 122(1):74-87. View abstract
  28. Cardiac Events During Competitive, Recreational, and Daily Activities in Children and Adolescents With Long QT Syndrome. J Am Heart Assoc. 2017 Sep 21; 6(9). View abstract
  29. Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders. Sci Rep. 2017 03 23; 7(1):346. View abstract
  30. Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ J. 2016 Dec 22; 81(1):12-21. View abstract
  31. Pausing With the Gauze: Inhibition of Temporary Pacemakers by Radiofrequency Scan During Cardiac Surgery. Anesth Analg. 2016 11; 123(5):1143-1148. View abstract
  32. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Dev Cell. 2016 11 21; 39(4):466-479. View abstract
  33. S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling. Arterioscler Thromb Vasc Biol. 2016 09; 36(9):1854-67. View abstract
  34. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. JCI Insight. 2016 Jun 16; 1(9). View abstract
  35. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 2015 Apr 07; 21(4):584-95. View abstract
  36. Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J Mol Cell Cardiol. 2014 Jul; 72:74-84. View abstract
  37. Saying yes to exercise and NO to cardiac injury. Circ Res. 2011 Jun 10; 108(12):1414-6. View abstract
  38. Rapid vesicular translocation and insertion of TRP channels. Nat Cell Biol. 2004 Aug; 6(8):709-20. View abstract
  39. SPIE- The International Society for Optical Engineering. Near-membrane protein dynamics revealed by evanescent field microscopy. 2004; (5467):326-337. View abstract
  40. Mechanism of persistent protein kinase D1 translocation and activation. Dev Cell. 2003 Apr; 4(4):561-74. View abstract
  41. The effects of buoyancy on sonoluminescing bubbles. Acoustics research letters online : ARLO. 2000; (1):12-18. View abstract
  42. The search for electrical discharges from single- and multi-bubble sonoluminescence. The Journal of the Acoustical Society of America. 1999; 1020(105). View abstract